Guggenheim lowered the firm’s price target on Veracyte (VCYT) to $45 from $50 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies in its diagnostics and life science tools coverage to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte Appoints Kevin Haas as Chief Technology Leader
- Veracyte names Kevin Haas as Chief Development and Technology Officer
- Veracyte price target lowered to $37 from $48 at Morgan Stanley
- Veracyte Inc. Signals Durable Growth in Earnings Call
- Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target